Alnylam director Stuart Arbuckle files Form 3 showing no ALNY holdings
Alnylam Pharmaceuticals, Inc. director Stuart A. Arbuckle filed an initial insider ownership report.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alnylam Pharmaceuticals, Inc. director Stuart A. Arbuckle filed an initial insider ownership report. This Form 3 indicates that, as of the event date of 01/05/2026, he holds no securities beneficially owned in Alnylam. The filing confirms his role as a director and that the report is filed by one reporting person.
The document also includes a power of attorney, under which Brett Budzinski signed on Arbuckle's behalf. This filing is primarily administrative, establishing Arbuckle’s status as an insider without disclosing any equity ownership or transactions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Form 3 filing reveal about ALNY director Stuart A. Arbuckle?
What is the relationship of Stuart A. Arbuckle to Alnylam Pharmaceuticals (ALNY)?
Who signed the Form 3 for Alnylam (ALNY) director Stuart A. Arbuckle?
Does this Alnylam (ALNY) Form 3 disclose any insider transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.